Evidence map›Paper›PMID 39944208›Full record

ArticleQatar medical journal2024

Epidemiology, clinical characteristics, and treatment outcomes of leishmaniasis in Qatar: A retrospective study.

Mohammed Abukhattab, Joanne Daghfal, Mohammed Adam, Samar A Hashim, Fathima Koolikkad Mohammed, Muna Al-Maslamani

Abstract read
In one paragraph

Article in Qatar medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohammed AbukhattabHamad Medical Corporation, Doha, Qatar *Email: mabukhattab@gmail.com.
Joanne DaghfalHamad Medical Corporation, Doha, Qatar *Email: mabukhattab@gmail.com.
Mohammed AdamHamad Medical Corporation, Doha, Qatar *Email: mabukhattab@gmail.com.
Samar A HashimHamad Medical Corporation, Doha, Qatar *Email: mabukhattab@gmail.com.
Fathima Koolikkad MohammedHamad Medical Corporation, Doha, Qatar *Email: mabukhattab@gmail.com.
Muna Al-MaslamaniHamad Medical Corporation, Doha, Qatar *Email: mabukhattab@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Leishmaniasis is an emerging tropical infectious disease in Qatar. It is caused by the protozoan parasite of the Methods: Using a retrospective cross-sectional study design, clinical and epidemiological data of all documented cases of leishmaniasis in Qatar between 2016 and 2022 were collected from electronic medical records at Hamad Medical Corporation (HMC). Results: A total of sixty-eight cases of leishmaniasis were detected in Qatar between 2016 and 2022. Males were predominant (69.12%) with a median age of 33 years. Our study revealed a higher incidence of leishmaniasis among individuals of Syrian nationality, followed by Pakistani and Sudanese, thus promoting further investigation into the underlying factors contributing to this health disparity. Our findings revealed important epidemiological trends, highlighted key clinical characteristics, identified risk factors associated with susceptibility to leishmaniasis, and reported treatment outcomes. Conclusion: This retrospective study presents the first comprehensive analysis of leishmaniasis in Qatar, shedding light on the epidemiology, clinical characteristics, and treatment outcomes of the disease. The data generated from this study can serve as a guide for authorities in establishing a national registry and treatment program for leishmaniasis in Qatar. Implementing these measures will contribute to the effective management and control of leishmaniasis, ultimately improving patient outcomes and public health in the country.

Indexed as

clinical characteristicsepidemiologyleishmaniasistreatment outcomes

Identifiers

PMID39944208
PMCPMC11814621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.